Scotiabank started coverage on shares of Alnylam Pharmaceuticals (NASDAQ:ALNY – Free Report) in a research note issued to ...

Prothena Corporation plc's stock has dropped 67% since my last “Buy” rating, primarily due to delays and a lack of meaningful ...

ALNY stock gains after submitting a regulatory application in the EU, seeking the approval of vutrisiran to treat ATTR ...

Several companies are developing new drugs treat transthyretin amyloidosis cardiomyopathy (ATTR-CM), an formerly obscure ...

Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNA interference (RNAi) therapeutics company, today announced the submission of a Type II Variation to the European Medicines Agency (EMA) for ...

Alnylam Pharmaceuticals (ALNY) announced the submission of a Type II Variation to the European Medicines Agency for vutrisiran, an ...

Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY – Get Free Report)’s stock price reached a new 52-week high on Tuesday after Bank of America raised their price target on the stock from $307.00 to $314.00.

Explore the ATTR amyloidosis treatment market, driven by innovative growing recognition of the condition, enhancing patient outcomes and quality of life.

Alnylam stock is in flat base and is offering a potential early entry. The biopharma company is hosting its Investor Day as earnings loom.

RNAi therapeutics company Alnylam Pharmaceuticals, Inc. (ALNY) announced Wednesday the submission of its supplemental New Drug ...

The FDA in 2022 approved Amvuttra to treat adults with polyneuropathy of hereditary transthyretin-mediated amyloidosis, a rare debilitating disease that damages nerves, and analysts have predicted ...

Intellia Therapeutics, Inc. NTLA announced that it has initiated the pivotal phase III HAELO study evaluating NTLA-2002 for ...